Initiation of pancreatic ductal adenocarcinoma (PDA) is definitively linked to activating
mutations in the KRAS oncogene. However, PDA mouse models show that mutant Kras …

Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …

Cancer metabolism is rewired to support cell survival in response to intrinsic and environmental
stressors. Identification of strategies to target these adaptions is an area of active …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease characterized by an
extensive fibroinflammatory stroma, which includes abundant cancer-associated fibroblast …

Here, we describe an unexpected cross-talk between Tregs and fibroblasts in pancreatic
cancer. Treg depletion resulted in differentiation of inflammatory fibroblast subsets, in turn …

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy
1 , 2 . This is mediated in part by a complex tumour microenvironment 3 , low vascularity 4 , …

This study shows that elevated apolipoprotein E in PDAC mediates immune suppression
and high serum apolipoprotein E levels correlate with poor patient survival. See related …

Pancreatic ductal adenocarcinoma (PDA) is accompanied by reprogramming of the local
microenvironment, but changes at distal sites are poorly understood. We implanted biomaterial …

Background & Aims New drug targets are urgently needed for the treatment of patients with
pancreatic ductal adenocarcinoma (PDA). Nearly all PDAs contain oncogenic mutations in …

Pancreatic ductal adenocarcinoma (PDA) is associated with activation of WNT signaling.
Whether this signaling pathway regulates the tumor microenvironment has remained …